LISTING OF CLAIMS:

Claim 1. (Previously Presented) An antibody molecule capable of specifically recognizing two regions of the β-A4 peptide/Aβ4, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof, wherein said antibody molecule comprises

(a) a variable V_L-Region comprising complementary determining regions, L-CDR1, L-CDR2, L-CDR3, wherein:

(1) L-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 96, 160, 175-177, 180, 189-190, 200-201, and 206-210;

(2) L-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 97 and 161; and

(3) L-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 18, 79, 81, 95, 149, 151-156, 158-159 and 166; and

(b) a variable V_H-Region comprising complementary determining regions, H-CDR1, H-CDR2, H-CDR3, wherein:

(1) H-CDR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 99 and 163;

(2) H-CDR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 100, 164, 167-169, 170-174, 179, 181-182, 184-188, 192-197, 199 and 204; and

(3) H-CDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 24.

Claim 2. (Original) The antibody molecule of claim 1, wherein said antibody molecule recognizes at least two consecutive amino acids within the two regions of β-A4.

Claim 3. (Previously Presented) The antibody molecule of claim 1, wherein said antibody molecule recognizes in the first region an amino acid sequence selected from the group consisting of EF, EFR, FR, and SEQ ID NOs: 415 – 418, and in the second region an amino acid sequence selected from the group consisting of LV and SEQ ID NOs: 419 - 423.

Claim 4. (Previously Presented) The antibody molecule of claim 1, wherein said antibody molecule comprises a variable V_H-region comprising a sequence selected from the group consisting of SEQ ID NOs: 6, 37, 39, 41, 43, 89, and 425.

Claim 5. (Previously Presented) The antibody molecule of claim 1, wherein said antibody molecule comprises a variable V_L-region comprising a sequence selected from the group consisting of SEQ ID NOs: 12, 51, 53, 57, and 91.

Claim 6. (Cancelled).

Claim 7. (Previously Presented) The antibody molecule of claim 1, wherein said antibody is selected from the group consisting of MSR-7 and an affinity-matured version of MSR-7.

Claim 8. (Previously Presented) The antibody molecule of claim 1, wherein said antibody molecule is a full antibody (immunoglobulin), a F(ab)-fragment, a

$F(ab)_2$-fragment, a single-chain antibody, a chimeric antibody, a CDR-grafted antibody, a bivalent antibody-construct, a synthetic antibody or a cross-cloned antibody.

Claim 9. (Previously Presented) The antibody molecule of claim 1, wherein said two regions of β-A4 form a conformational epitope or a discontinuous epitope.

Claim 10. (Cancelled).

Claim 11. (Previously Presented) A nucleic acid molecule encoding an antibody molecule according to claim 1.

Claim 12. (Original) A vector comprising the nucleic acid molecule of claim 11.

Claim 13. (Original) A host cell comprising the vector of claim 12.

Claim 14. (Previously Presented) A method for the preparation of an antibody molecule comprising culturing the host cell of claim 13 under conditions that allow synthesis of said antibody molecule and recovering said antibody molecule from said culture.

Claim 15. (Previously Presented) A pharmaceutical or diagnostic composition comprising an antibody molecule according to claim 1 and a carrier or diluent.

Claim 16. (Previously Presented) The composition of claim 15, which is a pharmaceutical composition.

Claims 17-21. (Cancelled).

Claim 22. (Previously Presented) A kit comprising an antibody molecule according to claim 1, a nucleic acid molecule according to claim 11, a vector according

to claim 12 or a host cell according to claim 13, wherein the antibody, nucleic acid, vector or host cell is contained in at least one vial, bottle, container or multicontainer unit.

Claims 23-28. (Cancelled).

Claim 29. (Previously Presented) A composition comprising an antibody molecule produced by the method of claim 14.

Claim 30. (Previously Presented) The composition of claim 16 further comprising a pharmaceutically acceptable carrier and/or diluent.

Claims 31-40. (Cancelled).

Claim 41. (Previously Presented) An antibody molecule comprising

(a) a variable V_L-Region comprising complementary determining regions, L-CDR1, L-CDR2, L-CDR3, wherein:

(1) L-CDR1 comprises SEQ ID NO: 143;

(2) L-CDR2 comprises SEQ ID NO: 144; and

(3) L-CDR3 comprises SEQ ID NO: 95; and

(b) a variable V_H-Region comprising complementary determining regions, H-CDR1, H-CDR2, H-CDR3, wherein:

(1) H-CDR1 comprises SEQ ID NO: 146;

(2) H-CDR2 comprises SEQ ID NOs: 192; and

(3) H-CDR3 comprises SEQ ID NOs: 93.

Claim 42. (Previously Presented)The antibody molecule according to claim 41, wherein the antibody is of the IgG1 subtype.

Claim 43. (Previously Presented) The antibody molecule according to claim 41, wherein the variable V_H-region comprises SEQ ID NO: 89; and the variable V_L-region comprises SEQ ID NO: 91.

Claim 44. (Previously Presented) The antibody molecule according to claim 43, wherein the antibody is of the IgG1 subtype.

Claim 45. (Previously Presented) The antibody molecule according to claim 41, wherein the variable V_H-region comprises SEQ ID NO: 425; and the variable V_L-region comprises SEQ ID NO: 91.

Claim 46. (Previously Presented) The antibody molecule according to claim 45, wherein the antibody is of the IgG1 subtype.

Claim 47. (Previously Presented) A pharmaceutical composition comprising an antibody molecule according to claim 41 and a pharmaceutically acceptable carrier or diluent.

Claim 48. (Previously Presented) A pharmaceutical composition comprising an antibody molecule according to claim 44 and a pharmaceutically acceptable carrier or diluent.

Claim 49. (Previously Presented) A pharmaceutical composition comprising an antibody molecule according to claim 46 and a pharmaceutically acceptable carrier or diluent.